logo
episode-header-image
Sep 2019
45m 25s

Dr. Ben Sessa - Preliminary Results from...

PSYCHEDELICS TODAY
About this episode

In this episode, Kyle and Joe interview Ben Sessa, a Consultant Psychiatrist. Ben comes on the show to talk about preliminary results from the first ever, MDMA assisted therapy for alcohol use disorder (AUD).

3 Key Points:

  1. Ben Sessa plays a role in leading the current MDMA assisted therapy study for alcohol use disorder, and shares preliminary results.
  2. In the current stage, out of the first 12 patients, 2 have turned back to drinking, 5 have stayed completely dry and another 5 who have had a drink or two but have not relapsed back to their typical levels of consumption.
  3. Most people with a long term substance addiction have a history of trauma. MDMA can help people feel safe, in order to work through and heal trauma.

Support the show

Navigating Psychedelics


Trip Journal                                               Integration Workbook


Show Notes

Preliminary Results

  • They had 13 people in the study, and they took data on 4 people
  • The first caveat in these results is that there was no blinding and no placebo in this study
    • There is no way to tell that it was solely the drug that resulted in the effects
  • In terms of tolerability, everyone preferred it to other treatment, there were no bad reactions to the MDMA, there were no negative reactions, it was a total success in terms of tolerability
  • In the current stage, out of the first 12 patients, 2 have turned back to drinking, 5 have stayed completely dry and another 5 who have had a drink or two but have not relapsed back to their typical levels of consumption
    • They did a similar study previous to this one except without the MDMA and they had 11 patients, 9 of them went back to their full level of consumption
  • They chose alcohol use disorder because it's so difficult to treat
  • All patients are recruits from local drug and alcohol services
    • Ben picks them up after they have detoxed, after they have been cured of the physical dependence, but when they have yet to be cured of the psychological dependence
  • They receive 2 dosing days within their 8 week therapy (usually weeks 3 and 6)
    • They do 125mg and then half that size dose 2 hours later, which sustains the high
  • Ben mentions that recruitment is difficult, a lot of people have a drinking problem, but they can't have patients that are depressed, suicidal, pregnant, epileptic, etc.

Future for the Study

  • Up until next March, they are continuing to take in new patients for the study to have more data
  • The next step is to have a randomized control study
  • This current study is sponsored by Imperial College of London
    • It's not a MAPS sponsored study, it's the first non MAPS, MDMA study
  • The main papers, with all the data are over a year and a half away from publishing

Addiction and Trauma

  • “MDMA addiction is as rare as a hen with teeth.” - Ben
  • “Most people with a long term substance addiction have a history of trauma.” - Ben
  • Trauma and PTSD is highly treatment resistant
  • There are certain drugs that inhibit fear response, such as alcohol, heroin, etc
    • They make you forget the pain but you can't work with them and do therapy with them, with MDMA you can
  • MDMA can help people feel safe, in order to work through and heal trauma
  • “We are all the products of our attachment relationships.” - Ben

Breaking Convention

  • This past year was the 5th one
  • There were 1300 attendees from all over the world
  • What's wonderful about Breaking Convention is how multidisciplinary it is
    • There's the guy in the gray suit in one room talking about high level neuroscience and a hippie with dreads in the other room talking about the spirits that live in the Salvia leaves
    • Ben says they work really hard to make that balance work
  • There's a lot of debate and conflict in the psychedelic movement right now,
    • Breaking Convention is very important for creating space for this debate

Looking ahead

  • Ben is looking into opening a clinic
  • He mentions academia is not his area of study, he is a clinician, but this research is an excuse to treat patients

Links

Breaking Convention


About Ben Sessa

Ben Sessa is a consultant psychiatrist in adult addictions, working part-time at Addaction in Weston-Super-Mare and is senior research fellow at Bristol, Cardiff and Imperial College London Universities, where he is currently taking time off clinical medical practice to study towards a PhD in MDMA Psychotherapy. He has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have lead him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. He is the author of two books exploring psychedelic medicine; The Psychedelic Renaissance (2012) and To Fathom Hell or Soar Angelic (2015) and is currently conducting research with Imperial College London and Cardiff universities studying the potential role for MDMA-assisted therapy for the treatment of PTSD and alcohol dependence syndrome. Dr Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use. He is a co-founder and director of the UK’s Breaking Convention conference.

Up next
Jul 8
PT 613 - Daniel Pinchbeck - From Cultural Catalyst to Capitalist Co-optation: Reflections on Psychedelic Science, AI, and Idealist Monism
In this expansive episode of Psychedelics Today, Joe Moore sits down with author and cultural theorist Daniel Pinchbeck to explore the evolving—and increasingly contested—role of psychedelics in society. From the hopeful spirit of transformation that animated earlier psychedelic ... Show More
1h 9m
Jul 3
PT 612 - Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning
In this wide-ranging conversation, journalist Mattha Busby joins Joe Moore to reflect on the shifting tone of the psychedelic movement in the wake of Psychedelic Science 2025. Based in Vancouver, Mattha has written for The Guardian, VICE, Esquire, TIME, and Wired, bringing a uniq ... Show More
1h 16m
Jul 1
PT 611 - Dylan Beynon - Mindbloom
Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S. Dylan shares the de ... Show More
1h 33m
Recommended Episodes
Nov 2018
MDMA for alcohol dependence, Music and sleep, Interoceptive skills, Parasites and entrepreneurship
Claudia Hammond finds out how MDMA assisted psychotherapy could help treat people with alcohol dependence. Trials are in their early stages but initial results are promising. Could this in the future be a new way to treat an addiction which ordinarily can have high relapse rates? ... Show More
28 m
Sep 2021
Dr. Matthew Johnson: Psychedelics for Treating Mental Disorders
This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ... Show More
2h 49m
Jun 2023
The Science of MDMA & Its Therapeutic Uses: Benefits & Risks
In this episode, I discuss Methyl​enedioxy​methamphetamine (MDMA), which is also commonly known as “ecstasy” or “molly,” including how it works in the brain to cause short- and long- term-shifts in emotional processing and its clinical applications for the treatment of post-traum ... Show More
2h 13m
Jun 2020
16. Veterans & Psychedelics part 2 – Ayahuasca for PTSD with Dr. Kate Pate & Nathan Pohl
War continues to hurt people long after the fighting has stopped. Veterans suffering from post-traumatic stress often self-medicate with alcohol or they are prescribed a cocktail of anti-depressants and opioids. This story is far too common for Nathan Pohl, A US veteran who serve ... Show More
34m 34s
Jul 2020
21. Drugs and consciousness with Professor Roland Griffiths
In this episode of the Drug Science podcast, Professor Nutt is joined by an old friend who he has known for 35 years. Professor Roland Griffiths is a researcher who has examined a wide range of psychotropic substances through the years. He has studied, the abuse potential of a nu ... Show More
46m 36s
May 2023
Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health
In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain ... Show More
2h 32m
Aug 2019
#65 - Rick Doblin, Ph.D.: MDMA— the creation, scheduling, toxicity, therapeutic use, and changing public opinion of what is possibly the single most important synthetic molecule ever created by our sp
In this episode, Rick Doblin, founder and executive director of MAPS, discusses MDMA, a molecule that has (at a minimum) revolutionary therapeutic benefits for PTSD, but arguably could have, at the highest order, a lasting impact on humanity’s ability to peacefully coexist. Rick ... Show More
3 h
Oct 2022
Dr. Nolan Williams: Psychedelics & Neurostimulation for Brain Rewiring
In this episode, my guest is Nolan Williams, M.D., a triple board-certified psychiatrist, neurologist and professor of psychiatry and behavioral sciences at Stanford School of Medicine. He is also the Director of the Stanford Brain Stimulation Lab. We discuss clinical application ... Show More
2h 44m
Sep 2021
MDMA for PTSD with Rick Doblin
Rick Doblin, psychotherapist and the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), returns to chat about methylenedioxymethamphetamine (MDMA) and its positive effects on PTSD and trauma.Today, Doblin share what MDMA is, how it ... Show More
15m 56s